These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 17329198)

  • 1. Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL.
    Soverini S; Martinelli G; Colarossi S; Gnani A; Rondoni M; Castagnetti F; Paolini S; Rosti G; Baccarani M
    Lancet Oncol; 2007 Mar; 8(3):273-4. PubMed ID: 17329198
    [No Abstract]   [Full Text] [Related]  

  • 2. Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
    Redaelli S; Piazza R; Rostagno R; Magistroni V; Perini P; Marega M; Gambacorti-Passerini C; Boschelli F
    J Clin Oncol; 2009 Jan; 27(3):469-71. PubMed ID: 19075254
    [No Abstract]   [Full Text] [Related]  

  • 3. Dasatinib in chronic myelogenous leukemia.
    Chu SC; Tang JL; Li CC
    N Engl J Med; 2006 Sep; 355(10):1062-3; author reply 1063-4. PubMed ID: 16960978
    [No Abstract]   [Full Text] [Related]  

  • 4. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib is effective in imatinib-resistant CML.
    Cannell E
    Lancet Oncol; 2007 Apr; 8(4):286. PubMed ID: 17431950
    [No Abstract]   [Full Text] [Related]  

  • 6. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
    Abbott BL
    Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic myeloid leukemia with e19a2 atypical transcript: early imatinib resistance and complete response to dasatinib.
    Martin SE; Sausen M; Joseph A; Kingham BF
    Cancer Genet Cytogenet; 2010 Sep; 201(2):133-4. PubMed ID: 20682399
    [No Abstract]   [Full Text] [Related]  

  • 8. Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib.
    Quintás-Cardama A; Kantarjian H; Cortes J
    Future Oncol; 2006 Dec; 2(6):655-65. PubMed ID: 17155893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chronic myeloid leukemia and resistance to tyrosine kinase inhibitors: ABL mutations, much ado about nothing?].
    Gómez Casares MT; León LG
    Med Clin (Barc); 2013 Aug; 141(3):111-3. PubMed ID: 23462544
    [No Abstract]   [Full Text] [Related]  

  • 10. Management of Bcr-Abl-positive leukemias with dasatinib.
    Hochhaus A
    Expert Rev Anticancer Ther; 2007 Nov; 7(11):1529-36. PubMed ID: 18020922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib.
    Loglisci G; Breccia M; Nanni M; Mancini M; De Cuia R; Cannella L; Salaroli A; Federico V; Serrao A; Loglisci MG; Santopietro M; Alimena G
    Leuk Lymphoma; 2011 Jul; 52(7):1372-5. PubMed ID: 21463110
    [No Abstract]   [Full Text] [Related]  

  • 12. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
    Talpaz M; Shah NP; Kantarjian H; Donato N; Nicoll J; Paquette R; Cortes J; O'Brien S; Nicaise C; Bleickardt E; Blackwood-Chirchir MA; Iyer V; Chen TT; Huang F; Decillis AP; Sawyers CL
    N Engl J Med; 2006 Jun; 354(24):2531-41. PubMed ID: 16775234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of imatinib, dasatinib, nilotinib and INNO-406 in imatinib-resistant cell lines.
    Deguchi Y; Kimura S; Ashihara E; Niwa T; Hodohara K; Fujiyama Y; Maekawa T
    Leuk Res; 2008 Jun; 32(6):980-3. PubMed ID: 18191450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Looking beyond imatinib: next line of targeted drugs for CML shows promise.
    Hampton T
    JAMA; 2006 Jan; 295(4):369-70. PubMed ID: 16434621
    [No Abstract]   [Full Text] [Related]  

  • 15. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia.
    Soverini S; Martinelli G; Colarossi S; Gnani A; Castagnetti F; Rosti G; Bosi C; Paolini S; Rondoni M; Piccaluga PP; Palandri F; Giannoulia P; Marzocchi G; Luatti S; Testoni N; Iacobucci I; Cilloni D; Saglio G; Baccarani M
    J Clin Oncol; 2006 Nov; 24(33):e51-2. PubMed ID: 17114651
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment of imatinib-intolerant or -resistant CML patients].
    Kimura S
    Nihon Rinsho; 2012 Apr; 70 Suppl 2():304-8. PubMed ID: 23133972
    [No Abstract]   [Full Text] [Related]  

  • 17. Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis.
    Soverini S; Martinelli G; Rosti G; Iacobucci I; Baccarani M
    Pharmacogenomics; 2012 Aug; 13(11):1271-84. PubMed ID: 22920397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained complete molecular response of chronic myeloid leukemia after discontinuation of second-generation tyrosine kinase inhibitors.
    Aoki J; Ohashi K; Kobayashi T; Kakihana K; Hirashima Y; Sakamaki H
    Leuk Lymphoma; 2012 Jul; 53(7):1412-4. PubMed ID: 22168276
    [No Abstract]   [Full Text] [Related]  

  • 19. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
    Wongboonma W; Thongnoppakhun W; Auewarakul CU
    Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia.
    Taylor MJ; Scuffham PA
    Expert Rev Pharmacoecon Outcomes Res; 2009 Apr; 9(2):117-21. PubMed ID: 19402798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.